Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilpivirine + raltegravir
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TMC278 + raltegravir is a combination of two antiretroviral agents for HIV-1 treatment. Rilpivirine (TMC278) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent anti-HIV-1 activity and a high barrier to resistance. It inhibits HIV-1 reverse transcriptase, preventing viral DNA synthesis[2]. Raltegravir is an integrase strand transfer inhibitor that blocks HIV-1 integrase, preventing the integration of viral DNA into the host genome[1][5]. Used together, these drugs target separate essential steps of HIV replication: reverse transcription and genome integration. The combination is investigated for nucleoside-sparing regimens or multi-class resistant HIV.
- Other names
- rilpivirineTMC278TMC-278TMC 278raltegravir
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on rilpivirine + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilpivirine + raltegravir.